CoImmune
Business Services · North Carolina, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
4233 Technology Dr, Durham, North Caroli...Phone Number
(919) 287-6300Website
www.coimmune.comRevenue
$5.2 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About CoImmune
CoImmune is a privately held, clinical stage immuno-oncology company that will redefine cancer treatment using best-in-class cellular immunotherapies. The company's allogeneic CAR-CIK technology platform for liquid and solid tumors is a variation on CAR-T therapy that promises enhanced efficacy with greatly reduced toxicity. The company's autologous RNA-loaded dendritic cell technology for solid tumors uses amplified total tumor mRNA to program highly engineered dendritic cells to generate immune responses against neoantigens without the need to identify them.Explore more
CoImmune Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is CoImmune your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at CoImmune
Check if CoImmune has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once CoImmune has new funding data
Website visits: Recent activity has been detected on your website
Click to see if CoImmune had a recent Job posting/layoffs
Check out if CoImmune is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on CoImmune recently announced quarterly report
CoImmune, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when CoImmune launches new products
Recommended Actions
Reach out to Masked Content who joined CoImmune as Masked Content
Find 3 more new buyers
Compare Similar Companies to CoImmune
Compare insights from companies similar to CoImmune, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
CoImmune is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
CoImmune is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about CoImmune.
CoImmune financials insights
Gather financial insights about CoImmune, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$45M
CoImmune Tech Stack
A closer look at the technologies used by CoImmune
CoImmune News & Media
CoImmune Announces Publication of Review of Clinical Development Program for CMN-001 in Metastatic Renal Cell Carcinoma
- CMN-001 is a dendritic cell-based immunotherapy electroporated with autologous tumor RNA - - Phase 2b clinical trial combines CMN-001 with first-line checkpoint inhibition therapy and second line lenvatinib/everolimus - DURHAM, N.C., July 6, 2023 /PRNewswire/ -- CoImmune, Inc., a...CoImmune Announces Publication of Preclinical Data Demonstrating Efficacy and Specificity of CAR-CIK Cells in Acute Myeloid Leukemia
- Researchers target CD123+/CD33+ leukemic cells while minimizing toxicity against healthy cells - DURHAM, N.C., July 5, 2023 /PRNewswire/ -- CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today...CoImmune Obtains License to Target DLL3 with IL-18 Armored CAR Technology
- Technology will be coupled with modified Cytokine Induced Killer (CIK) cells in development program focused on solid tumors with initial trials in small cell lung cancer - DURHAM, N.C., June 27, 2023 /PRNewswire/ -- CoImmune, Inc., a clinical stage immuno-oncology company working to...CoImmune Obtains License to IL-18 Armored CAR Technology
Technology will be coupled with modified Cytokine Induced Killer (CIK) cells - Company selects CD19 as initial target and plans to launch clinical development program in B-cell malignancies - DURHAM, N.C., March 20, 2023 /PRNewswire/ -- CoImmune, Inc., a clinical stage immuno-oncology...
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding CoImmune
Sign Up For FreeTo access detailed company insights
CoImmune is a privately held, clinical stage immuno-oncology company that will redefine cancer treatment using best-in-class cellular immunotherapies. The company's allogeneic CAR-CIK technology platform for liquid and solid tumors is a variation on CAR-T therapy that promises enhanced efficacy with greatly reduced toxicity. The company's autologou... Read More
